Unit

UNIT 15.25 Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice

  1. Benoit Chassaing1,
  2. Jesse D. Aitken1,
  3. Madhu Malleshappa1,
  4. Matam Vijay-Kumar2,3

Published Online: 4 FEB 2014

DOI: 10.1002/0471142735.im1525s104

Current Protocols in Immunology

Current Protocols in Immunology

How to Cite

Chassaing, B., Aitken, J. D., Malleshappa, M. and Vijay-Kumar, M. 2014. Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice. Current Protocols in Immunology. 104:15.25:15.25.1–15.25.14.

Author Information

  1. 1

    Center for Inflammation, Immunity, & Infection, Department of Biology, Georgia State University, Atlanta, Georgia

  2. 2

    Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania

  3. 3

    Department of Medicine, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania

Publication History

  1. Published Online: 4 FEB 2014

Abstract

Inflammatory bowel diseases (IBD), mainly comprising ulcerative colitis and Crohn's Disease, are complex and multifactorial diseases with unknown etiology. For the past 20 years, to study human IBD mechanistically, a number of murine models of colitis have been developed. These models are indispensable tools to decipher underlying mechanisms of IBD pathogenesis as well as to evaluate a number of potential therapeutics. Among various chemically induced colitis models, the dextran sulfate sodium (DSS)-induced colitis model is widely used because of its simplicity and many similarities with human ulcerative colitis. This model has both advantages and disadvantages that must be considered when employed. This protocol describes the DSS-induced colitis model, focusing on details and factors that could affect DSS-induced pathology. Curr. Protoc. Immunol. 104:15.25.1-15.25.14. © 2014 by John Wiley & Sons, Inc.

Keywords:

  • chemical colitogen;
  • intestinal inflammation;
  • occult blood;
  • myeloperoxidase;
  • ulcerative colitis;
  • inflammatory bowel disease